Daily Archives: May 22, 2023
USPSTF Draft Statement recommends biennial screening mammography for women ages 40 to 74 years
22 May, 2023 | 13:56h | UTCBreast Cancer: Screening – U.S. Preventive Services Task Force
Critical perspectives on the statement:
Earlier screening for breast cancer: Benefits and harms – Lown Institute
Why more mammograms aren’t the solution to breast cancer – Vox
AGA/ACG Guideline | Pharmacological management of chronic idiopathic constipation
22 May, 2023 | 13:53h | UTC
Special Supplement | Labor and delivery at term – partograms, labor disorders, analgesia/anesthesia, and fever
22 May, 2023 | 13:51h | UTC
Global variations in heart failure etiology, management, and outcomes
22 May, 2023 | 13:50h | UTCGlobal Variations in Heart Failure Etiology, Management, and Outcomes – JAMA (free for a limited period)
Author Interview: Global Trends in Heart Failure Etiology, Management, and Outcomes
News Release: Heart failure deadly and under-treated in most countries, says a study in 40 countries – McMaster University
Commentary on Twitter
Study of patients with heart failure (HF) from 40 different countries and from 4 different economic levels demonstrated differences in HF etiologies, management, and outcomes. https://t.co/uYH9jI8Q5Z
— JAMA (@JAMA_current) May 16, 2023
ChatGPT’s performance on radiology board exam: strengths and shortcomings
22 May, 2023 | 13:48h | UTCNews Release: ChatGPT passes radiology board exam – Radiological Society of North America
RCT | Remote pulmonary artery monitoring may improve QoL, reduce hospitalizations in symptomatic (NYHA III) heart failure
22 May, 2023 | 13:47h | UTCRemote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial – The Lancet (link to abstract – $ for full-text)
News Release: Remote monitoring reduces heart failure hospitalisations and improves quality of life – European Society of Cardiology
Commentary: CardioMEMS Beats Standard Care in First European RCT: MONITOR-HF – TCTMD
Commentary on Twitter
Remote monitoring reduces #HeartFailure hospitalisations and improves quality of life 👇#HeartFailure2023 #HF #HFA_ESC #MONIT0R_HF pic.twitter.com/Rvg1y45tCQ
— European Society of Cardiology (@escardio) May 20, 2023
RCT | Apixaban fails to match warfarin in preventing valve thrombosis in On-X mechanical heart valve patients
22 May, 2023 | 13:44h | UTCApixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve – NEJM Evidence
Commentary: Apixaban or Warfarin in Patients With On-X Mechanical Aortic Valve – American College of Cardiology
Commentary on Twitter
“…in patients with an On-X mechanical aortic valve, apixaban was not noninferior to warfarin and failed to meet our safety threshold… for the prevention of valve thrombosis or valve-related thromboembolism.” https://t.co/XEcOJiGIYU#CardioTwitter #Afib
— NEJM Evidence (@NEJMEvidence) May 11, 2023
AHA Statement | Addressing diabetes and atherosclerosis in Asian American adults: insights, management, future steps
22 May, 2023 | 13:42h | UTCNews Release: Culture, diet, economic factors and more affect CVD risk among Asian Americans – American Heart Association
Commentary: Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says – TCTMD
Commentary on Twitter
Examining Asian American subgroups separately is crucial to understanding different mechanisms that contribute to T2D & ASCVD risks. The new scientific statement: https://t.co/taTVvXtXd2 @CircAHA @kwancardio @SallySWong @alka_kanaya @HeartDocSadiya @SvatiShah @FFR81 @hayman_ll pic.twitter.com/lWtl1AKBKg
— AHA Science (@AHAScience) May 8, 2023
Underdiagnosis of primary aldosteronism: a review of screening and detection
22 May, 2023 | 13:40h | UTC
Commentary on Twitter
Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection https://t.co/PYzSCZD2L7 (FREE)@MarioFunesMD @BhallaResearch @StanfordNeph pic.twitter.com/k7intLqpK3
— AJKD (@AJKDonline) May 19, 2023
SCAI Consensus Statement | Management of in-stent restenosis and stent thrombosis
22 May, 2023 | 13:41h | UTCNews Release: Guidance on management of in-stent restenosis and stent thrombosis – Society for Cardiovascular Angiography and Interventions
Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies
22 May, 2023 | 13:38h | UTC
Commentary on Twitter
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation:https://t.co/f4BYxY69tk #hpbcsm #medonc #camoldx #camicroenv pic.twitter.com/lqmwgp9hxh
— NatureRevClinOncol (@NatRevClinOncol) May 16, 2023
Digitally-enabled remote critical care: will it make problems of geography history?
22 May, 2023 | 13:36h | UTC
RCT | Ruxolitinib achieves greater molecular response and EFS in hydroxycarbamide-resistant Polycythemia Vera
22 May, 2023 | 13:35h | UTCCommentary: Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype – Cancer Network
Editorial | Selective digestive decontamination – Pro
22 May, 2023 | 13:34h | UTCSelective digestive decontamination – Pro – Intensive Care Medicine (free for a limited period)
Commentary on Twitter
#SDD? One of few areas in critical care where large RCTs/SRs demonstrate consistent advantage, without evident side effects. Pivotal
📃 standardized formulation/protocols
📚 education
🧫 ABT stewardship + rigorous IPC strategies, monitoring ABTs use/AMR
🖇️ https://t.co/VOqudX6E6k pic.twitter.com/YN5DuXknDL— Intensive Care Medicine (@yourICM) May 21, 2023
Drug-induced abnormal involuntary movements: prevalence and treatment
22 May, 2023 | 13:30h | UTC
RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment
22 May, 2023 | 13:32h | UTCFirst-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post
Commentary on Twitter
Venetoclax with obinutuzumab or rituximab as first-line treatment for pts with CLL & coexisting conditions has resulted in a large percentage of pts with undetectable minimal residual disease & long progression-free survival.
Read the Research Summary: https://t.co/2i45QN55Hz
— NEJM (@NEJM) May 14, 2023
M-A | Inhaled nitrous oxide for painful procedures in children and youth
22 May, 2023 | 13:29h | UTC
ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy
22 May, 2023 | 13:27h | UTC
Stenotrophomonas Maltophilia: review and meta-analysis of treatment options
22 May, 2023 | 13:25h | UTC
New pharmacological agents and novel cardiovascular pharmacotherapy strategies
22 May, 2023 | 13:24h | UTC
Commentary on Twitter
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022: a focused review by the ESC Working Group on #Pharmacotherapy 💊 https://t.co/DZ6FTqYwxk @jpkaski #HF #AFib #diabetes #lipids #EHJPharmacotherapy @AgewallStefan @FeliceGragnano pic.twitter.com/1DTCewbyPv
— European Society of Cardiology Journals (@ESC_Journals) May 20, 2023
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
22 May, 2023 | 13:23h | UTCEpidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology
Review | Sarcopenia and cardiovascular diseases
22 May, 2023 | 13:22h | UTCSarcopenia and Cardiovascular Diseases – Circulation